These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 27432042)

  • 1. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
    Comerota AJ; Ramacciotti E
    Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
    Imberti D; Pomero F; Mastroiacovo D
    Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
    Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
    Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.
    Sindet-Pedersen C; Pallisgaard JL; Olesen JB; Gislason GH; Arevalo LC
    Thromb Res; 2015 Oct; 136(4):732-8. PubMed ID: 26277682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
    Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
    Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral anticoagulants for primary and secondary prevention of venous thromboembolism].
    Gavorník P; Dukát A; Gašpar Ľ; Gubo G; Hučková N
    Vnitr Lek; 2016; 62(9):746-750. PubMed ID: 27715076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
    Dentali F; Fantoni C
    Intern Emerg Med; 2017 Aug; 12(5):565-567. PubMed ID: 28656545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.